Stanford scientists have developed a novel hydrogel for long-term drug delivery of an Activator Protein 1 (AP-1) inhibitor for the prevention of post-surgical abdominal adhesion.
Stanford researchers have developed a new, low-cost method for tumor methylation profiling that enables tumor classification even from low amounts of fragmented DNA characteristic of liquid biopsies.
Stanford inventors have developed a novel diagnostic tool that identifies distinct immune signatures in the peripheral blood of osteoarthritis patients using mass cytometry (CyTOF) and applied machine learning.
Stanford researchers have engineered retroviral and virus-like delivery systems for producing universal pseudotyped vehicles for cell and gene therapies.
A team of Stanford researchers has identified a group of small molecules that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
Stanford inventors have developed a method of using human induced pluripotent stem (hiPS) cells to generate three-dimensional neural floorplate organizers that are functionally active and capable of choreographing midline brain development.
Stanford researchers have developed novel technology that combines AAVMYO, a muscle cell targeting viral vector, with CRISPR base editors to achieve targeted gene repair, showcasing over 70% correction of hereditary mutations in cardiomyocytes.
Patients who experience heart attacks often have immediate ischemia and cell death, which causes a decrease in cardiac function, contributing to higher mortality and morbidity.
Stanford BIODESIGN researchers have developed a disease breathalyzer for detecting necrotizing enterocolitis in newborns. Newborn babies face a high risk of blood infections (sepsis) and gastrointestinal inflammation and injury disease (necrotizing enterocolitis 'NEC').
Stanford researchers have formulated a first in line framework called EcoTyper which systematically profiles the tumor microenvironment (TME) cell states in multiple solid tumor types, providing a platform for effective personalized cancer decisions.
Researchers at Stanford have developed a nucleic acid amplification test to detect high-risk Epstein-Barr Virus (EBV) BALF2 variants in plasma to aid population-level screening for nasopharyngeal carcinoma (NPC).
Researchers at Stanford have developed an inducible and programmable CRISPR-mediated transcript organization (CRISPR-TO) method for repositioning RNAs to various desired subcellular compartments.